Reach Us +1-217-403-9671
Challenges For Preparation Of Module 2 & 5 For BA/ BE For US & EMEA | 8376
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Challenges for preparation of module 2 & 5 for BA/ BE for US & EMEA

International Conference & Exhibition Bioequivalence and Bioavailability

Neerja S

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

C ommon Technical Document for the Registration of Pharmaceuticals for Human Use (CTD) represents the agreed upon common format for the preparation of a well- structured harmonized application that will be submitted to regulatory authorities of US FDA, EMEA and Japan. The Clinical data required in Module 2 & 5 is different for a New drug application and a Generic application. For a CTD of Generic application the Module 2 contain Clinical overview and clinical summary data of the Bioequivalence/ Bioavailability studies performed and in Module 5 the study report(s) of Bioequivalence/ Comparative Bioavailability under conditions of Fed/ Fast with their annexures. Individual Case Report forms are also a part of this module. As the US, EU and Japan are not geographically similar; their documentary arrangements are also not the same. The differences major in US and EU CTD wrt to Module 2 and 5 are; ? US FDA requires a table for ? Reanalysis of Study samples ? where as this is not applicable to EMEA. ? The table ? Composition of Meal Used in Fed Bioequivalence Study ? is a requirement for US FDA where as the same is not required for EMEA. ? Literature References - Copies of referenced documents, including important published articles, official meeting minutes, or other regulatory guidance or advice should be provided for EMEA filing were as a the literature is readily available in the site of Office of Generic drugs. USFDA. Similar type of differences is there which needs special attention and understanding before filing in US and EU in CTD format